-
ACCESS TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ANTIOBESITY MEDICATIONS: FORMULARY COVERAGE AND PRIOR AUTHORIZATION RESTRICTIONS ACROSS U.S. PAYERS
Mar 18, 2026, 21:38 PM -
QUANTIFYING CDA-INESSS DIFFERENCES IN ONCOLOGY HTA: RECOMMENDATIONS, RE-ANALYSIS, AND PRICE REDUCTIONS (2024-2025)
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF DPYD-GUIDED FOLFOX IN UNRESECTABLE METASTATIC COLORECTAL CANCER IN THE US: A PATIENT-LEVEL MICROSIMULATION MODEL
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE GLOBAL ECONOMIC BURDEN OF HEPATITIS DELTA VIRUS: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
REAL-WORLD CONCORDANCE WITH THE FRAMINGHAM STROKE RISK MODEL IN ATRIAL FIBRILLATION AND IDENTIFICATION OF ADDITIONAL SIGNIFICANT FEATURES
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF A MULTI-AGENT "DEEP" AI SYSTEM FOR HEOR EVIDENCE AND INTELLIGENCE GENERATION
Mar 18, 2026, 21:38 PM -
HETEROGENEOUS RESPONSES TO BRAZIL’S PHARMACEUTICAL PRICE CAP REGULATION: EVIDENCE FROM PRIVATE INSURANCES AND THE UNIFIED HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
ASSESSING THE VALUE OF LOST SCHOOLING DUE TO ILLNESS AMONG CHILDREN IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION (HRU) AND COST BURDEN IN NON-METASTATIC MELANOMA IN THE MODERN TREATMENT ERA: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)-MEDICARE ANALYSIS
Mar 18, 2026, 21:38 PM -
HUMANISTIC BURDEN IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) USING PATIENT-REPORTED OUTCOME MEASURES (PROMS)
Mar 18, 2026, 21:38 PM -
A SYSTEMATIC REVIEW OF FINDINGS AND METHODS IN ECONOMIC EVALUATIONS OF DYADIC HEALTHCARE INTERVENTIONS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF PROCALCITONIN-GUIDED ANTIBIOTIC THERAPY IN ADULT PATIENTS WITH ACUTE RESPIRATORY INFECTION IN A COLOMBIAN REFERRAL HOSPITAL
Mar 18, 2026, 21:38 PM -
MODELLING HEALTH SYSTEM CAPACITY AND MEASUREMENT DISPERSION TO EXPLAIN CROSS-NATIONAL VARIATION IN EQVT UTILITY VALUES
Mar 18, 2026, 21:38 PM -
PATTERNS AND PREDICTORS OF LUNG CANCER CARE TRAJECTORIES: A SEQUENCE ANALYSIS OF INSURANCE CLAIMS
Mar 18, 2026, 21:38 PM -
GLOBAL AVAILABILITY AND ACCESS TO EVIDENCE-BASED ANTI-OBESITY PHARMACOTHERAPIES: A SYSTEMATIC ASSESSMENT OF REGULATORY AND REIMBURSEMENT LANDSCAPES
Mar 18, 2026, 21:38 PM -
THE TOTAL COST OF CARE AND BUDGET IMPACT OF INTRODUCING MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN FOR SECOND-LINE OR LATER (2L+) TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) TO A UNITED STATES (US) HEALTH PLAN
Mar 18, 2026, 21:38 PM -
UPDATED COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB VEDOTIN COMBINED WITH CHEMOIMMUNOTHERAPY FOR UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN CHINA: EVIDENCE FROM LONG-TERM FOLLOW-UP OF THE POLARIX ASIAN SUBGROUP
Mar 18, 2026, 21:38 PM -
PRIORITIZING AND COSTING RMNCH INNOVATIONS FOR SCALABLE IMPACT: A COMBINED MCDA AND COSTING APPROACH FROM ETHIOPIA
Mar 18, 2026, 21:38 PM -
DELAYED DIAGNOSIS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) AMONG PATIENTS TREATED WITH TAFAMIDIS
Mar 18, 2026, 21:38 PM -
MODELLING ASSOCIATIONS BETWEEN EXTREME POVERTY TRAJECTORIES AND POPULATION GROWTH FOR HEALTH SYSTEMS PLANNING
Mar 18, 2026, 21:38 PM
